Want news about Pfizer to land in your mailbox?


Pfizer an outperformer: Prabhudas Lilladher
Prabhudas Lilladher has maintained its outperformer rating on Pfizer with a target price of Rs 732 in its July 1, 2008 research report. "We expect the company to report 7% CAGR net sales and 14% CAGR net profit over FY07-09. We also expect its EBIDTA margin to improve from 22.5% in FY07 to 24.7% in FY09 due to the restructuring."
"At the CMP of Rs 551, the stock trades at 11.3x FY08E EPS of Rs 48.9 and 9.8x FY09E EPS of Rs 56.3. We maintain Outperformer rating on the scrip with a price target of Rs 732 (13x FY09 earnings) over the next 12 months, an upside of 33.0% over the CMP," says Lilladher's research report.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
|
RSS feed for news |
For further details click on attachment.......
Attachments : Pfizer-1-7-08-PL.pdf |
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
Martin Pieters
MD and CEO
Vodafone
See major growth opportunities in rural India: Vodafone
Rakesh Parikh
VP-Finance
Unichem Lab
Domestic formulations to grow significantly ahead: Unichem
Koshi Varghese
Executive VP-Marketing
MRF
Input costs hitting margins, see tyre price hike ahead: MRF
Venkat Jasti
Chief Executive Officer
Suven Life Sciences
See 25% growth in CRAMS biz next year: Suven Life Sciences
-
Most Read
-
Most Viewed
- Mkts to react –ve to RBI rate hike move on Monday: Experts
- Raamdeo Agrawal's top sector picks for your portfolio

- Will RBI's policy rate hike impact corporates, borrowers?
- Persistent IPO clocks highest bid in 26 mths at 93.6 times
- 10-15% mkt rise in a month not good for India: Blackstone

- RBI ups repo, reverse repo rates by 0.25%
- Shree Ganesh Jewellery IPO opens; should you subscribe?
- Shankar Sharma's 1-yr trading ban with effect March 19: SAT
- Expert strategies to trade markets next week

- Persistent Systems: Experts give industry & stock outlook

- Jewellers head to Dalal Street
Source: Business Line
- Nissan to build plug-in car in UK
Source: ft.com
- Mystery Shopper: Kurtis and cattle in Mumbai
Source: ft.com
- Shree Ganesh plans to raise Rs 375 cr via IPO
Source: Business Line

















